XSWX
SOON
Market cap14bUSD
Jun 18, Last price
196.40CHF
1D
-0.71%
1Q
10.03%
Jan 2017
60.22%
IPO
57.79%
Name
Sonova Holding AG
Chart & Performance
P/E
21.59
P/S
3.02
EPS
9.10
Div Yield, %
2.22%
Shrs. gr., 5y
-1.44%
Rev. gr., 5y
5.79%
Revenues
3.87b
+6.58%
Net income
541m
-10.07%
CFO
794m
+5.36%
Dividend
Jun 13, 20254.4 CHF/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Stäfa, Switzerland, Sonova Holding AG is a leading provider of innovative hearing care solutions for both adults and children. The company's operations are divided into two primary segments: Hearing Instruments and Cochlear Implants. Sonova's extensive offerings include advanced wireless communication devices, rechargeable hearing aids, wireless headsets, speech-enhanced hearables, premium audiophile headphones, microphones, and wireless transmission systems, alongside comprehensive audiological care services. Its renowned hearing aid brands comprise Phonak, Unitron, and Hansaton, while Advanced Bionics is its flagship for cochlear implants. For consumer audio, Sonova offers products under the Sennheiser brand. The company delivers its audiological care through a vast network of around 3,600 clinics and stores operating under various regional names such as AudioNova, Audium, and Boots Hearingcare, among others. Additionally, its products are distributed via independent partners. Sonova boasts a significant international presence, serving markets across the United States, Europe, the Middle East, Africa, and the Asia Pacific. Founded in 1947, the company was formerly known as Phonak Holding AG before officially changing its name to Sonova Holding AG in August 2007.
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||